Trial · NCT07910435
Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial
NCT07910435, Phase 2, Not yet recruiting, University of Washington
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial. Trials, record NCT07910435. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910435
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial
- NCT number
- NCT07910435
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 27 participants, estimated
- Lead sponsor
- University of Washington
- Conditions
- Mantle Cell Lymphoma
- Interventions
Polatuzumab Vedotin, Acalabrutinib, Mosunetuzumab, Bone Marrow Biopsy, Core Biopsy, FDG-Positron Emission Tomography and Computed Tomography Scan, Neurologic Examination, Patient Observation, Biospecimen Collection, Bone Marrow Aspiration
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Positron emission tomography complete response (CR) rate | After 17 cycles of induction therapy (cycle length = 21 days) | Will consider this regimen successful and merit further investigation if the observed CR rate after 17 cycles of therapy is ≥ 85%. |
| Secondary | Progression-free survival | From start of therapy to disease progression, or death, assessed up to 5 years | Time to event endpoints will be estimated using the Kaplan-Meier method, and the median time to event and its corresponding 95% confidence interval will be calculated. |
| Secondary | Event-free survival | From start of therapy to failure to achieve at least partial response, receipt of non-protocol therapy (not including maintenance or consolidation), disease progression, or death, assessed up to 5 years | Time to event endpoints will be estimated using the Kaplan-Meier method, and the median time to event and its corresponding 95% confidence interval will be calculated. |
| Secondary | Overall survival | From start of therapy to death from any cause, assessed up to 5 years | Time to event endpoints will be estimated using the Kaplan-Meier method, and the median time to event and its corresponding 95% confidence interval will be calculated. |
| Secondary | Duration of response among patients who achieve CR or partial response (PR) | From the date of first response (CR or PR) to disease progression or death, assessed up to 5 years | Time to event endpoints will be estimated using the Kaplan-Meier method, and the median time to event and its corresponding 95% confidence interval will be calculated. |
| Secondary | Duration of complete response among patients who achieve CR | From the date of first complete response to disease progression or death, assessed up to 5 years | Time to event endpoints will be estimated using the Kaplan-Meier method, and the median time to event and its corresponding 95% confidence interval will be calculated. |
| Secondary | Incidence of adverse events | Up to 90 days after last dose | The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be reported. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910435
GET https://conductscience.org/api/trials/v1/NCT07910435/registered